Jie Zhang
Stephanie C. Dulawa*- Department of Psychiatry, University of California, San Diego, San Diego, CA, United States
Anorexia nervosa (AN) is a severe eating disorder that primarily affects young women and girls, and is characterized by abnormal restrictive feeding and a dangerously low body-mass index. AN has one of the highest mortality rates of any psychiatric disorder, and no approved pharmacological treatments exist. Current psychological and behavioral treatments are largely ineffective, and relapse is common. Relatively little basic research has examined biological mechanisms that underlie AN compared to other major neuropsychiatric disorders. A recent large-scale genome-wide association study (GWAS) revealed that the genetic architecture of AN has strong metabolic as well as psychiatric origins, suggesting that AN should be reconceptualized as a metabo-psychiatric disorder. Therefore, identifying the metabo-psychiatric mechanisms that contribute to AN may be essential for developing effective treatments. This review focuses on animal models for studying the metabo-psychiatric mechanisms that may contribute to AN, with a focus on the activity-based anorexia (ABA) paradigm. We also highlight recent work using modern circuit-dissecting neuroscience techniques to uncover metabolic mechanisms that regulate ABA, and encourage further work to ultimately identify novel treatment strategies for AN.
Introduction
Anorexia nervosa (AN) is a complex and serious illness primarily characterized by a low body-mass index (BMI), fear of gaining weight, and body image disturbance. Patients with AN also frequently engage in compulsive exercise. AN predominantly affects women and girls, with clinical populations showing a 10:1 female-to-male ratio (1, 2). The onset of illness is typically during middle to late adolescence, and runs a disabling and chronic course with up to 4% in lifetime prevalence (3). AN has one of the highest mortality rates of any psychiatric disorder, with a weighted mortality rate of 5.1 deaths per 1,000 person-years from meta-analysis (4). Relapse is frequent in individuals with AN despite receiving treatment, with reported rates ranging between 9 and 52% (5). Certain cognitive traits have been associated with AN and precede onset of the illness, including cognitive rigidity, anxiety, and perfectionism (6). Strong genetic correlations have been identified between the heritability of AN and other psychiatric disorders, namely obsessive-compulsive disorder, major depressive disorder, and schizophrenia (1). Thus, elucidating biological mechanisms in AN may also shed light on the underpinnings of other related psychiatric conditions and traits.
Recent findings from genetic, neuroimaging, metabolic, and microbiome studies in humans have provided important leads for animal model studies investigating the metabo-psychiatric mechanisms underlying AN. For example, a recent GWAS combining data from the Anorexia Nervosa Genetics Initiative and the Eating Disorders Working Group identified significant genetic correlations of AN with metabolic traits and psychiatric disorders, suggesting that AN should be reconceptualized as a metabo-psychiatric disorder (1). Low BMI has traditionally been thought to result from core psychological features of AN, such as a drive for thinness. Yet, this view has failed to explain the extreme difficulty that AN patients face in the recovery and maintenance of a healthy BMI. These novel genetic data strongly suggest that metabolic traits contribute significantly to the development of AN (1, 7, 8) and should also be a target for treatment. Indeed, current treatments focusing only on nutritional restorations and psychological symptoms have been largely ineffective (5, 9). Furthermore, neuroimaging studies have identified alterations in the density of dopamine receptors in AN (10) which have subsequently been found to alter metabolism in preclinical studies (11). Future research efforts into the etiology and treatment of AN should target metabolic mechanisms gone awry in the disorder to develop novel treatment strategies.
Preclinical work using animal models to investigate biological mechanisms underlying core features of AN has not been prioritized for several reasons. One is the historical focus on sociocultural factors thought to contribute to eating disorders, which may make animal models appear unfeasible. Two, the mistaken perception that an animal model should recapitulate all aspects of a disorder may also discourage the development of animal models for studying aspects of AN (12). In fact, the current approach to developing animal models for studying neuropsychiatric disorders is to model only an aspect or a core feature of the disorder, and determine whether the model exhibits predictive validity (12). Developing a model with a more narrow use often leads to pragmatic advantages in the conduct of mechanistic studies, and can also increase the confidence in the cross-species validity of the model (12). A substantial increase in animal model work will be required to identify the metabo-psychiatric underpinnings of AN.
Our review highlights the utility of animal models for studying the metabo-psychiatric origins of AN. Recent work has combined the ABA paradigm with other modern techniques including circuit-dissecting approaches, genetic approaches, and gut microbiome manipulations. We review recent findings in this area, and encourage more preclinical work studying how metabolic mechanisms influence behaviors relevant to AN (Figure 1).
Figure 1. Framework for improving the utility of animal models of AN. Leads from human findings can be further tested and refined using animal models to elucidate the metabo-psychiatric origins of AN, and explore novel treatments. Findings from animal models can also generate testable hypotheses for human studies of AN. GWAS, genome-wide association study.
Section 1. Overview of Activity-Based Anorexia
A commonly used biobehavioral animal model for aspects of AN is the activity-based anorexia (ABA) paradigm. In the ABA paradigm, rodents exposed to time-restricted feeding and constant running wheel access rapidly reduce food intake and bodyweight, and paradoxically develop hyperactivity (13). In contrast, rodents subjected to the same time-restricted feeding schedule without access to running wheels maintain body weight indefinitely. During ABA, rodents develop hypothermia (14, 15), loss of estrus, and increases in HPA axis activity (16, 17); if allowed to continue unchecked, ABA results in death (18). Importantly, the ABA phenomenon is highly conserved across mammalian species, and makes some accurate predictions about AN (18). For example, AN typically onsets during adolescence (6, 7), and younger rodents develop ABA more readily than older rodents (19, 20). Furthermore, female rats, and mice are more vulnerable to ABA than male rodents (18, 21), paralleling the female preponderance in AN.
The ABA paradigm recapitulates a core feature of AN, which is a paradoxical response to negative energy balance. In AN, individuals restrict feeding and engage in compulsive exercise while in a state of negative energy balance. When exposed to the ABA paradigm, rodents reduce voluntary food intake, and increase wheel running even as they progressively lose weight. The increase in wheel running in the ABA paradigm has been suggested to reflect increased foraging behavior (22). This hyperactivity often peaks before food delivery, and is termed food anticipatory activity (FAA), and has also been reported in AN patients (23). However, the ABA model does not recapitulate all aspects of AN. For example, providing high-fat food during the paradigm prevents the development of ABA (24). Furthermore, restoration of ad-lib feeding typically results in recovery of mice to a normal body weight (25), while AN patients do not readily recover only with presentation of food. Regardless, the ABA paradigm provides a useful model for a specific aspect of AN, which is the paradoxical response to negative energy balance under homeostatic feeding conditions.
Using the ABA model to identify metabolic mechanisms contributing to AN represents a tailored use of the model, which may lead to pragmatic advantages and aid in establishing cross-species validity (12). The ABA paradigm is ideally suited for assessing metabolic measures, and can be readily performed within metabolic chambers (26). The utility of the ABA paradigm for modelling cognitive aspects of AN is less well-established, although several reports lend support to this idea (27–29). Finally, the biological processes regulating feeding, activity, and metabolism are thought to be highly conserved between rodents and humans (30, 31), further supporting their use for studying metabolic mechanisms relevant to AN.
Section 2. Use of the ABA Paradigm to Identify Metabo-Psychiatric Mechanisms in AN
Most studies using the ABA paradigm have assessed only basic readouts of metabolic function including bodyweight, food intake, and wheel running activity during ad libitum vs. time-scheduled feeding. Far fewer studies have assessed metabolic measures more comprehensively. Modern circuit-dissecting approaches have identified some of the neural circuits that regulate metabolism in the context of ABA, although much work remains to be done in this area. Here, we highlight recent preclinical findings regarding the metabo-psychiatric mechanisms underlying ABA, including the role of the hypothalamic nuclei, striatal dopaminergic system, and gut-brain axis (Figure 2).
Figure 2. Schematic representation of rodent brain circuits and neural substrates implicated in the regulation of activity-based anorexia. Solid lines indicate established circuits, and dashed lines show potential circuits regulating the ABA phenomenon through effects on food intake, locomotor activity, FAA, or metabolic function. Primary neural substrates are listed in accordance with their brain regions. mPFC, Medial prefrontal cortex; NAc, Nucleus accumbens; ARC, Arcuate Nucleus; LHA, Lateral hypothalamus; VTA, Ventral tegmental area; NPY, Neuropeptide Y; AgRP, Agouti-related peptide; GLUT, glutamate; GABA, gamma-aminobutyric acid; DA, dopamine; D1R- and D2R-MSNs, dopamine D1 and D2 receptor expressing medium spiny neurons.
The hypothalamus is perhaps one of the most studied central brain regions which coordinates physiological and behavioral homeostasis and motivated behaviors including feeding and foraging (32, 33). It is thereby not surprising that altered hypothalamic structure and connectivity have been implicated in the emergence of AN. For example, neuroimaging studies have described increased connectivity within the arcuate nucleus (ARC) but decreased connectivity within the lateral hypothalamus, as well as neurochemical imbalances in AN patients following a meal (34–36). However, whether these and other structural and functional changes are a cause or consequence of AN remains unclear. Animal studies using the ABA paradigm have since assisted in probing the mechanisms by which hypothalamic dysregulation contributes to aspects of AN.
Agouti-related protein (AgRP)- and neuropeptide Y (NPY)-expressing neurons located within the ARC are activated by energy deficits and promote food-seeking behaviors and consumption (37). AN patients have been reported to have elevated plasma AgRP levels (38), and elevated concentrations of NPY in cerebrospinal fluid (39). In parallel, animals exhibit significantly higher AgRP/NPY mRNA levels in the ARC during ABA (40, 41), while intracerebroventricular infusion of NPY facilitates ABA by increasing running activity and decreasing food intake (42). Recent work using fiber photometry has provided novel insights into the role of AgRP neurons in regulating metabo-psychiatric processes underlying the ABA phenomenon. For example, Miletta et al. (24) demonstrated that ablation of AgRP neurons in the early postnatal period prevents fuel mobilization during ABA conditions, resulting in reduced running wheel activity and marked weight loss, whereas chemogenetic activation of AgRP neurons increases running wheel activity and extends survival in the paradigm. Furthermore, they also reported that AgRP neuron activity rapidly decreases with termination of running, revealing a novel role for AgRP neurons in regulating compulsive running behavior during ABA. Duriez et al. (40) reported complex effects of food restriction and running wheel availability on mRNA levels of AgRP and NPY. Specifically, they reported that mRNA levels of AgRP and NPY are increased during short- and long-term food restriction (2 vs. 10 weeks, respectively), but that the presence of a running wheel attenuates this increase. Further studies using modern circuit-dissecting approaches should clarify the complex role of AgRP and NPY in regulating metabo-psychiatric mechanisms of ABA.
Located exclusively in the lateral hypothalamus (LHA), orexin is another key neuropeptide thought to modulate reward, feeding, and activity (43). Orexin neurons project widely throughout the brain, and densely innervate the ARC (44). Plasma orexin-A levels have been reported to be elevated in untreated AN patients in some studies (45), and reduced in others (46). Orexin neuronal activity is rapidly inhibited following food consumption, while ablation of orexin neurons promotes overeating and obesity (47). Orexin neuron activity is increased during FAA (48, 49), and elevated spontaneous physical activity (SPA), which refers to physical activity not motivated by a reward. Furthermore, orexin neuron-ablated mice do not exhibit FAA when exposed to ABA conditions (49). Higher SPA levels have been reported to predict greater weight loss during ABA (50). Furthermore, when AgRP and orexin levels fail to upregulate during ABA in a rat model of passive stress coping, these rats lose weight more rapidly (51). More work will be required to clarify the role of orexin neuron activity in regulating ABA.
A large body of literature has implicated the striatal dopaminergic system in the etiology of AN. Much of this evidence comes from human neuroimaging studies revealing altered striatal function during tasks assessing reward, altered dopamine (DA) receptor levels, or altered dopamine metabolites (10, 52, 53). Recently, a small number of preclinical research studies have implicated the striatal dopaminergic system in metabolic processes affecting ABA. For example, chemogenetic excitation of the ventral tegmental area (VTA) to nucleus accumbens (NAc) pathway in female rats prevents weight loss during ABA by increasing food intake and FAA, without altering overall activity (54). Furthermore, hyperdopaminergia resulting from dopamine transporter knockdown accelerates the progression of ABA (55). Recently, viral overexpression of the D2 receptor expressing on the medium spiny neurons (D2-MSNs) of the nucleus accumbens core (D2R-OENAc) was reported to induce rapid and robust weight loss in female, but not male, mice during ABA under mild food-restriction conditions. Of note, this sexually-dimorphic effect was also observed without running wheel access, and without alterations in food intake. In addition, D2R-OENAc mice showed robust glucose intolerance in the intraperitoneal glucose tolerance test (11), confirming a previous report that D2Rs in the NAc regulate glucose metabolism (56). Furthermore, experiments using chemogenetic approaches have revealed a role for cortico-striatal projections from medial prefrontal cortex (mPFC) to NAc shell in regulating body weight and activity during ABA (28), and these projections are modulated by dopamine (57). In summary, these findings highlight the need for more research to better characterize the role of striatal dopaminergic dynamics in ABA.
Mesolimbic DA neurons also detect peripheral signals relaying information regarding appetite and energy intake, such as leptin and ghrelin. Altered circulating concentrations of the orexigenic hormone ghrelin and the anorexigenic leptin have been reported in AN patient (58, 59). Mice treated with ghrelin increased food intake during ABA, although bodyweight was not affected (60). Furthermore, plasma ghrelin levels have been positively correlated with FAA, which can be suppressed by a ghrelin receptor (GHS-R1A) antagonist (61). Increases in ghrelin and reductions in leptin levels are thought to drive hyperactivity by directly altering the activity of dopamine neurons in the VTA (22). Complex dysfunction of nutrient-sensing systems may play a role in AN and involve interactions with the dopamine system, which regulates behavioral responses to food cues and influences energy homeostasis.
Section 3. Use of the ABA Paradigm to Study the Role of the Gut-Brain Axis in AN
The gut microbiota is a complex community of trillions of microorganisms residing in the gastrointestinal tract, affecting both physiological and psychological health (62). The gut-brain axis has drawn more attention in AN research recently, as a fast growing body of literature suggests that alterations in gut microbiota might influence features of AN, including host energy hemostasis, appetite and body weight regulation, gastrointestinal symptomatology, and neurobehavioral traits including anxiety (63, 64). AN patients have been reported to exhibit gut dysbiosis, with imbalances in multiple microbes (8, 63). Interestingly, gut dysbiosis may be persistent even after short-term weight restoration in AN (65), suggesting that disrupted equilibrium of gut microbiota might be a causative factor in AN. However, the cause-effect relationship between the gut microbiota and AN still remains unclear. Studies using animal models will be essential for expanding our understanding of how the gut-brain axis contributes to AN pathology, beyond correlative findings.
Recently, preclinical research has substantiated that exposure to ABA conditions can affect gut microbiota composition and diversity primarily through metabolic processes induced by food restriction and the resulting negative energy balance (66, 67). ABA conditions have also been reported to induce specific proteome adaptations in gut bacteria favoring ATP production in response to the energy-restricted state of the host (68). On the other hand, the mechanisms by which gut microbiota influence AN risk and trajectory have yet to be determined. One study explored this direction by transplanting fecal microbiota derived from AN patients vs. healthy controls into germ-free mice. Interestingly, gut microbiome derived from AN patients significantly hindered the recipient mice from gaining body weight, and reduced in food intake and food efficiency ratio (body weight gain/food intake). Moreover, mice receiving fecal microbiota from AN patients also exhibit elevated anxiety-like behaviors in open field and marble-burying tests compared to mice receiving fecal microbiota from controls (69). Another report, in contrast, found no difference in body weight and lean/fat mass between AN recipient mice and control recipient mice after 4 weeks of colonization (70). However, neither study measured bodyweight or food intake under food restriction conditions, and only assessed these measures during ad-lib feeding. Studies employing the same strategy but testing animal recipients in the ABA paradigm will be essential to better understand whether the AN-derived gut microbiota contributes to the development of AN-like phenotypes.
Section 4. Other Animal Models for Studying Metabo-Psychiatric Traits in AN
AN has an estimated twin-based heritability ranging from 30–80%, suggesting a strong genetic component to the risk of disease development. A recent large-scale GWAS identified eight significant loci that were associated with AN, including CADM1, FOXP1, and PTBP2, which are all expressed in the hypothalamus and other brain regions (1). Yet, these loci still require fine mapping in order to confirm the involvement of these genes. Once the functional consequences of these loci have been determined, genetic mouse models can be produced that will be essential for identifying AN disease mechanisms. Furthermore, GWAS could also be performed in mice to identify loci which regulate ABA, and these could be compared with the recent GWAS findings in AN.
Prior to the recent GWAS findings in AN, several animal studies reported mutations which induce a phenotype similar to AN. Early work reported that the anx/anx mice model mimics aspects of AN, including suppressed appetite and food intake, emaciated appearance, and premature death (71). Notably, the spontaneous anx mutation identified in mice induces abnormalities within the hypothalamus, involving an aberrant AgRP/NPY system (64, 72). Additionally, anx/anx mice display decreases in hypothalamic activity accompanied by impaired glucose utilization and energy metabolism (73). However, it remains unknown which gene is responsible for the phenotype of anx/anx mice, or whether AN patients show variation within the responsible gene.
A recent study reported that brain-specific knockout of SIRT1, a metabolic regulator responding to stress and nutrient availability, protects mice from ABA, while overexpression promotes the development of ABA including weight loss, hyperactivity, and anxiety (74). Although SIRT1 has not been identified as a risk gene for AN in large-scale human genetic studies, these findings are consistent with metabo-psychiatric underpinnings of AN.
Adverse social and developmental experiences have been identified as risk factors for AN, and several animal models, especially maternal separation-based protocols, have been generated to examine the links between environmental influence and AN-related phenotypes (9). For example, maternal separation combined with time-restricted feeding alters the expression of genes involved in lipid and energy metabolism (75). Intriguingly, post-weaning isolation rearing induces FAA only in female mice during ABA (76), and maternal separation was found to upregulate DA expressing cells in the VTA on ABA rats in a sex-dependent manner (77). Furthermore, prenatal stress was reported to accelerate the progression of weight loss during ABA in passive stress-coping rats due to impairments of AgRP and orexin gene upregulation. Passive stress-coping rats are also suggested to have innate impairments in leptin and ghrelin in responses to starvation, which may underlie decreased food intake and associated heightened body weight loss during ABA (51). Prenatal stress was also found to accelerate ABA progression through the hypomethylation of placental miR-340, a sexually dimorphic regulator of nutrient transporters (78). Thus, environmental factors can induce epigenetic changes leading to metabolic alterations in rodent models, and thus may also be involved in triggering AN symptomatology in humans. In addition to the genetic and environmental models of AN highlighted here, others have been systematically reviewed elsewhere (29).
Conclusion and Future Perspective
In summary, animal models are undoubtedly critical for identifying the metabo-psychiatric basis of AN and accelerating the discovery of novel treatments. Limitations to animal models for investigating AN include their inability to mimic certain psychological factors of the disorder including body image disturbances and fear of gaining weight. However, these limitations do not negate their usefulness for identifying the metabo-psychiatric mechanisms underlying the disorder. In particular, the ABA paradigm remains a promising and useful experimental preparation, especially when used in combination with modern circuit-dissecting techniques. Future research should pursue how traditionally viewed distinct circuits for metabolic regulation vs. psychiatric phenotypes interact to produce AN-like phenotypes. In addition, the development of new genetic and epigenetic animal models based on recent GWAS findings should have far-reaching impact. Another essential feature of AN and the ABA phenomenon which requires further mechanistic study is the robust sex difference in which females show far greater vulnerability. Indeed, recent work has revealed striatal manipulations which result in robust sex differences in vulnerability to ABA (11). In conclusion, animal models will be essential for identifying metabo-psychiatric mechanisms underlying vulnerability to AN, and for identifying the role of newly discovered genetic variants and gene pathways in AN.
Author Contributions
JZ and SD conceptualized the manuscript. JZ wrote the first draft of the paper and constructed the figures. SD thoroughly reviewed and revised the manuscript. All authors finalized the manuscript.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Acknowledgments
We thank scidraw.io for mouse illustrations.
Abbreviations
ABA, activity-based anorexia; AgRP, agouti-related protein; AN, anorexia nervosa; ARC, arcuate nucleus; BMI, body-mass index; DA, dopamine; D1R- and D2R-MSNs, dopamine D1 and D2 receptor expressing medium spiny neurons; GHS-R1A, growth hormone secretagogue receptor 1A; GWAS, genome-wide association study; FAA, food anticipatory activity; LHA, lateral hypothalamus; mPFC, medial prefrontal cortex; NPY, neuropeptide Y; NAc, nucleus accumbens; SPA, spontaneous physical activity; VTA, Ventral tegmental area.
References
1. Watson HJ, Yilmaz Z, Thornton LM, Hubel C, Coleman JRI, Gaspar HA, et al. Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa. Nat Genet. (2019) 51:1207–14. doi: 10.1038/s41588-019-0439-2
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association Publishing (2013). p. 338–45. doi: 10.1176/appi.books.9780890425596
3. Smink FR, van Hoeken D, Hoek HW. Epidemiology, course, and outcome of eating disorders. Curr Opin Psychiatry. (2013) 26:543–8. doi: 10.1097/YCO.0b013e328365a24f
4. Arcelus J, Mitchell AJ, Wales J, Nielsen S. Mortality rates in patients with anorexia nervosa and other eating disorders. A meta-analysis of 36 studies. Arch Gen Psychiatry. (2011) 68:724–31. doi: 10.1001/archgenpsychiatry.2011.74
5. Khalsa SS, Portnoff LC, McCurdy-McKinnon D, Feusner JD. What happens after treatment? A systematic review of relapse, remission, and recovery in anorexia nervosa. J Eat Disord. (2017) 5:20. doi: 10.1186/s40337-017-0145-3
6. Kaye WH, Bulik CM, Thornton L, Barbarich N, Masters K. Comorbidity of anxiety disorders with anorexia and bulimia nervosa. Am J Psychiatry. (2004) 161:2215–21. doi: 10.1176/appi.ajp.161.12.2215
7. Zipfel S, Giel KE, Bulik CM, Hay P, Schmidt U. Anorexia nervosa: aetiology, assessment, and treatment. Lancet Psychiatry. (2015) 2:1099–111. doi: 10.1016/S2215-0366(15)00356-9
8. Bulik CM, Flatt R, Abbaspour A, Carroll I. Reconceptualizing anorexia nervosa. Psychiatry Clin Neurosci. (2019) 73:518–25. doi: 10.1111/pcn.12857
9. Attia E. Anorexia nervosa treatment trials: time for new approaches. Lancet Psychiatry. (2021) 8:170–1. doi: 10.1016/S2215-0366(21)00038-9
10. Frank GK, Kaye WH. Current status of functional imaging in eating disorders. Int J Eat Disord. (2012) 45:723–36. doi: 10.1002/eat.22016
11. Welch AC, Zhang J, Lyu J, McMurray MS, Javitch JA, Kellendonk C, et al. Dopamine D2 receptor overexpression in the nucleus accumbens core induces robust weight loss during scheduled fasting selectively in female mice. Mol Psychiatry. (2019). doi: 10.1038/s41380-019-0633-8
12. Geyer MA, Markou A. Animal models of psychiatric disorders. In: Bloom F, Kupfer D, editors. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press (1995). p. 787–98.
13. Routtenberg A, Kuznesof AW. Self-starvation of rats living in activity wheels on a restricted feeding schedule. J Comp Physiol Psychol. (1967) 64:414–21. doi: 10.1037/h0025205
14. Lambert KG. The activity-stress paradigm: possible mechanisms and applications. J Gen Psychol. (1993) 120:21–32. doi: 10.1080/00221309.1993.9917859
15. Gutierrez E. A rat in the labyrinth of anorexia nervosa: contributions of the activity-based anorexia rodent model to the understanding of anorexia nervosa. Int J Eat Disord. (2013) 46:289–301. doi: 10.1002/eat.22095
16. Burden VR, White BD, Dean RG, Martin RJ. Activity of the hypothalamic-pituitary-adrenal axis is elevated in rats with activity-based anorexia. J Nutr. (1993) 123:1217–25. doi: 10.1093/jn/123.7.1217
17. Kinzig KP, Hargrave SL. Adolescent activity-based anorexia increases anxiety-like behavior in adulthood. Physiol Behav. (2010) 101:269–76. doi: 10.1016/j.physbeh.2010.05.010
18. Klenotich SJ, Dulawa SC. The activity-based anorexia mouse model. Methods Mol Biol. (2012) 829:377–93. doi: 10.1007/978-1-61779-458-2_25
19. Pare WP. The influence of food consumption and running activity on the activity-stress ulcer in the rat. Am J Dig Dis. (1975) 20:262–73. doi: 10.1007/BF01070729
20. Chowdhury TG, Rios MB, Chan TE, Cassataro DS, Barbarich-Marsteller NC, Aoki C. Activity-based anorexia during adolescence disrupts normal development of the CA1 pyramidal cells in the ventral hippocampus of female rats. Hippocampus. (2014) 24:1421–9. doi: 10.1002/hipo.22320
21. Doerries LE, Stanley EZ, Aravich PF. Activity-based anorexia: relationship to gender and activity-stress ulcers. Physiol Behav. (1991) 50:945–9. doi: 10.1016/0031-9384(91)90419-O
22. Adan RA, Hillebrand JJ, Danner UN, Cano CS, Kas MJ, Verhagen LA. Neurobiology driving hyperactivity in activity-based anorexia. Curr Top Behav Neurosci. (2011) 6:229–50. doi: 10.1007/7854_2010_77
23. Scheurink AJ, Boersma GJ, Nergardh R, Sodersten P. Neurobiology of hyperactivity and reward: agreeable restlessness in anorexia nervosa. Physiol Behav. (2010) 100:490–5. doi: 10.1016/j.physbeh.2010.03.016
24. Miletta MC, Iyilikci O, Shanabrough M, Sestan-Pesa M, Cammisa A, Zeiss CJ, et al. AgRP neurons control compulsive exercise and survival in an activity-based anorexia model. Nat Metab. (2020) 2:1204–11. doi: 10.1038/s42255-020-00300-8
25. Dixon DP, Ackert AM, Eckel LA. Development of, and recovery from, activity-based anorexia in female rats. Physiol Behav. (2003) 80:273–9. doi: 10.1016/j.physbeh.2003.08.008
26. Byerly MS, Swanson R, Wei Z, Seldin MM, McCulloh PS, Wong GW, et al. Central role for C1q/TNF-related protein 13 (CTRP13) in modulating food intake and body weight. PLoS ONE. (2013) 8:e62862. doi: 10.1371/journal.pone.0062862
27. Rokot NT, Ataka K, Iwai H, Suzuki H, Tachibe H, Kairupan TS, et al. Antagonism for NPY signaling reverses cognitive behavior defects induced by activity-based anorexia in mice. Psychoneuroendocrinology. (2021) 126:105133. doi: 10.1016/j.psyneuen.2021.105133
28. Milton LK, Mirabella PN, Greaves E, Spanswick DC, van den Buuse M, Oldfield BJ, et al. Suppression of corticostriatal circuit activity improves cognitive flexibility and prevents body weight loss in activity-based anorexia in rats. Biol Psychiatry. (2020). doi: 10.1016/j.biopsych.2020.06.022
29. Scharner S, Stengel A. Animal models for anorexia nervosa-A systematic review. Front Hum Neurosci. (2020) 14:596381. doi: 10.3389/fnhum.2020.596381
30. Pembroke WG, Hartl CL, Geschwind DH. Evolutionary conservation and divergence of the human brain transcriptome. Genome Biol. (2021) 22:52. doi: 10.1186/s13059-020-02257-z
31. Monaco G, van Dam S, Casal Novo Ribeiro JL, Larbi A, de Magalhaes JP. A comparison of human and mouse gene co-expression networks reveals conservation and divergence at the tissue, pathway and disease levels. BMC Evol Biol. (2015) 15:259. doi: 10.1186/s12862-015-0534-7
32. Saper CB, Lowell BB. The hypothalamus. Curr Biol. (2014) 24:R1111–6. doi: 10.1016/j.cub.2014.10.023
33. Bonnavion P, Mickelsen LE, Fujita A, de Lecea L, Jackson AC. Hubs and spokes of the lateral hypothalamus: cell types, circuits and behaviour. J Physiol. (2016) 594:6443–62. doi: 10.1113/JP271946
34. Frank GK, Shott ME, Riederer J, Pryor TL. Altered structural and effective connectivity in anorexia and bulimia nervosa in circuits that regulate energy and reward homeostasis. Transl Psychiatry. (2016) 6:e932. doi: 10.1038/tp.2016.199
35. Stern SA, Bulik CM. Alternative frameworks for advancing the study of eating disorders. Trends Neurosci. (2020) 43:951–9. doi: 10.1016/j.tins.2020.10.001
36. Florent V, Baroncini M, Jissendi-Tchofo P, Lopes R, Vanhoutte M, Rasika S, et al. Hypothalamic structural and functional imbalances in anorexia nervosa. Neuroendocrinology. (2020) 110:552–62. doi: 10.1159/000503147
37. Sternson SM, Eiselt AK. Three pillars for the neural control of appetite. Annu Rev Physiol. (2017) 79:401–23. doi: 10.1146/annurev-physiol-021115-104948
38. Moriya J, Takimoto Y, Yoshiuchi K, Shimosawa T, Akabayashi A. Plasma agouti-related protein levels in women with anorexia nervosa. Psychoneuroendocrinology. (2006) 31:1057–61. doi: 10.1016/j.psyneuen.2006.06.006
39. Kaye WH, Berrettini W, Gwirtsman H, George DT. Altered cerebrospinal fluid neuropeptide Y and peptide YY immunoreactivity in anorexia and bulimia nervosa. Arch Gen Psychiatry. (1990) 47:548–56. doi: 10.1001/archpsyc.1990.01810180048008
40. Duriez P, Nilsson IAK, Le Thuc O, Alexandre D, Chartrel N, Rovere C, et al. Exploring the mechanisms of recovery in anorexia nervosa through a translational approach: from original ecological measurements in human to brain tissue analyses in mice. Nutrients. (2021) 13:2786. doi: 10.3390/nu13082786
41. de Rijke CE, Hillebrand JJ, Verhagen LA, Roeling TA, Adan RA. Hypothalamic neuropeptide expression following chronic food restriction in sedentary and wheel-running rats. J Mol Endocrinol. (2005) 35:381–90. doi: 10.1677/jme.1.01808
42. Nergardh R, Ammar A, Brodin U, Bergstrom J, Scheurink A, Sodersten P. Neuropeptide Y facilitates activity-based-anorexia. Psychoneuroendocrinology. (2007) 32:493–502. doi: 10.1016/j.psyneuen.2007.03.002
43. Rossi MA, Stuber GD. Overlapping brain circuits for homeostatic and hedonic feeding. Cell Metab. (2018) 27:42–56. doi: 10.1016/j.cmet.2017.09.021
44. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci. (2007) 8:171–81. doi: 10.1038/nrn2092
45. Bronsky J, Nedvidkova J, Krasnicanova H, Vesela M, Schmidtova J, Koutek J, et al. Changes of orexin A plasma levels in girls with anorexia nervosa during eight weeks of realimentation. Int J Eat Disord. (2011) 44:547–52. doi: 10.1002/eat.20857
46. Janas-Kozik M, Stachowicz M, Krupka-Matuszczyk I, Szymszal J, Krysta K, Janas A, et al. Plasma levels of leptin and orexin A in the restrictive type of anorexia nervosa. Regul Pept. (2011) 168:5–9. doi: 10.1016/j.regpep.2011.02.005
47. Gonzalez JA, Jensen LT, Iordanidou P, Strom M, Fugger L, Burdakov D. Inhibitory interplay between orexin neurons and eating. Curr Biol. (2016) 26:2486–91. doi: 10.1016/j.cub.2016.07.013
48. Zink AN, Perez-Leighton CE, Kotz CM. The orexin neuropeptide system: physical activity and hypothalamic function throughout the aging process. Front Syst Neurosci. (2014) 8:211. doi: 10.3389/fnsys.2014.00211
49. Kaur S, Thankachan S, Begum S, Blanco-Centurion C, Sakurai T, Yanagisawa M, et al. Entrainment of temperature and activity rhythms to restricted feeding in orexin knock out mice. Brain Res. (2008) 1205:47–54. doi: 10.1016/j.brainres.2008.02.026
50. Perez-Leighton CE, Grace M, Billington CJ, Kotz CM. Role of spontaneous physical activity in prediction of susceptibility to activity based anorexia in male and female rats. Physiol Behav. (2014) 135:104–11. doi: 10.1016/j.physbeh.2014.06.001
51. Boersma GJ, Liang NC, Lee RS, Albertz JD, Kastelein A, Moody LA, et al. Failure to upregulate agrp and orexin in response to activity based anorexia in weight loss vulnerable rats characterized by passive stress coping and prenatal stress experience. Psychoneuroendocrinology. (2016) 67:171–81. doi: 10.1016/j.psyneuen.2016.02.002
52. Kaye WH, Frank GK, McConaha C. Altered dopamine activity after recovery from restricting-type anorexia nervosa. Neuropsychopharmacology. (1999) 21:503–6. doi: 10.1016/S0893-133X(99)00053-6
53. Frank GK, Bailer UF, Henry SE, Drevets W, Meltzer CC, Price JC, et al. Increased dopamine D2/D3 receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [11c]raclopride. Biol Psychiatry. (2005) 58:908–12. doi: 10.1016/j.biopsych.2005.05.003
54. Foldi CJ, Milton LK, Oldfield BJ. The role of mesolimbic reward neurocircuitry in prevention and rescue of the activity-based anorexia (ABA) phenotype in rats. Neuropsychopharmacology. (2017) 42:2292–300. doi: 10.1038/npp.2017.63
55. Beeler JA, Mourra D, Zanca RM, Kalmbach A, Gellman C, Klein BY, et al. Vulnerable and resilient phenotypes in a mouse model of anorexia nervosa. Biol Psychiatry. (2020). doi: 10.1016/j.biopsych.2020.06.030
56. Michaelides M, Miller ML, DiNieri JA, Gomez JL, Schwartz E, Egervari G, et al. Dopamine D2 receptor signaling in the nucleus accumbens comprises a metabolic-cognitive brain interface regulating metabolic components of glucose reinforcement. Neuropsychopharmacology. (2017) 42:2365–76. doi: 10.1038/npp.2017.112
57. Domingo-Rodriguez L, de Azua IR, Dominguez E, Senabre E, Serra I, Kummer S, et al. A specific prelimbic-nucleus accumbens pathway controls resilience versus vulnerability to food addiction. Nat Commun. (2020) 11:782. doi: 10.1038/s41467-020-14458-y
58. Hebebrand J, Muller TD, Holtkamp K, Herpertz-Dahlmann B. The role of leptin in anorexia nervosa: clinical implications. Mol Psychiatry. (2007) 12:23–35. doi: 10.1038/sj.mp.4001909
59. Schalla MA, Stengel A. The role of ghrelin in anorexia nervosa. Int J Mol Sci. (2018) 19:2117. doi: 10.3390/ijms19072117
60. Legrand R, Lucas N, Breton J, Azhar S, do Rego J-C, Dechelotte P, et al. Ghrelin treatment prevents development of activity based anorexia in mice. Eur Neuropsychopharmacol. (2016) 26:948–58. doi: 10.1016/j.euroneuro.2016.03.010
61. Verhagen LA, Egecioglu E, Luijendijk MC, Hillebrand JJ, Adan RA, Dickson SL. Acute and chronic suppression of the central ghrelin signaling system reveals a role in food anticipatory activity. Eur Neuropsychopharmacol. (2011) 21:384–92. doi: 10.1016/j.euroneuro.2010.06.005
62. Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ. (2018) 361:k2179. doi: 10.1136/bmj.k2179
63. Reed KK, Abbaspour A, Bulik CM, Carroll IM. The intestinal microbiota and anorexia nervosa: cause or consequence of nutrient deprivation. Curr Opin Endocr Metab Res. (2021) 19:46–51. doi: 10.1016/j.coemr.2021.06.003
64. Nilsson I, Lindfors C, Fetissov SO, Hokfelt T, Johansen JE. Aberrant agouti-related protein system in the hypothalamus of the anx/anx mouse is associated with activation of microglia. J Comp Neurol. (2008) 507:1128–40. doi: 10.1002/cne.21599
65. Schulz N, Belheouane M, Dahmen B, Ruan VA, Specht HE, Dempfle A, et al. Gut microbiota alteration in adolescent anorexia nervosa does not normalize with short-term weight restoration. Int J Eat Disord. (2021) 54:969–80. doi: 10.1002/eat.23435
66. Trinh S, Kogel V, Voelz C, Schlosser A, Schwenzer C, Kabbert J, et al. Gut microbiota and brain alterations in a translational anorexia nervosa rat model. J Psychiatr Res. (2021) 133:156–65. doi: 10.1016/j.jpsychires.2020.12.030
67. Queipo-Ortuno MI, Seoane LM, Murri M, Pardo M, Gomez-Zumaquero JM, Cardona F, et al. Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels. PLoS ONE. (2013) 8:e65465. doi: 10.1371/journal.pone.0065465
68. Breton J, Legrand R, Achamrah N, Chan P, do Rego JL, do Rego JC, et al. Proteome modifications of gut microbiota in mice with activity-based anorexia and starvation: role in ATP production. Nutrition. (2019) 67–68:110557. doi: 10.1016/j.nut.2019.110557
69. Hata T, Miyata N, Takakura S, Yoshihara K, Asano Y, Kimura-Todani T, et al. The gut microbiome derived from anorexia nervosa patients impairs weight gain and behavioral performance in female mice. Endocrinology. (2019) 160:2441–52. doi: 10.1210/en.2019-00408
70. Glenny EM, Fouladi F, Thomas SA, Bulik-Sullivan EC, Tang Q, Djukic Z, et al. Gut microbial communities from patients with anorexia nervosa do not influence body weight in recipient germ-free mice. Gut Microbes. (2021) 13:1–15. doi: 10.1080/19490976.2021.1897216
71. Nilsson IAK. The anx/anx mouse - a valuable resource in anorexia nervosa research. Front Neurosci. (2019) 13:59. doi: 10.3389/fnins.2019.00059
72. Broberger C, Johansen J, Schalling M, Hokfelt T. Hypothalamic neurohistochemistry of the murine anorexia (anx/anx) mutation: altered processing of neuropeptide Y in the arcuate nucleus. J Comp Neurol. (1997) 387:124–35. doi: 10.1002/(sici)1096-9861(19971013)387:1<124::aid-cne10>3.0.co;2-u
73. Bergstrom U, Lindfors C, Svedberg M, Johansen JE, Haggkvist J, Schalling M, et al. Reduced metabolism in the hypothalamus of the anorectic anx/anx mouse. J Endocrinol. (2017) 233:15–24. doi: 10.1530/JOE-16-0383
74. Robinette TM, Nicholatos JW, Francisco AB, Brooks KE, Diao RY, Sorbi S, et al. SIRT1 accelerates the progression of activity-based anorexia. Nat Commun. (2020) 11:2814. doi: 10.1038/s41467-020-16348-9
75. Zgheib S, Mequinion M, Lucas S, Leterme D, Ghali O, Tolle V, et al. Long-term physiological alterations and recovery in a mouse model of separation associated with time-restricted feeding: a tool to study anorexia nervosa related consequences. PLoS ONE. (2014) 9:e103775. doi: 10.1371/journal.pone.0103775
76. Hurel I, Redon B, Scocard A, Malezieux M, Marsicano G, Chaouloff F. Beyond the activity-based anorexia model: reinforcing values of exercise and feeding examined in stressed adolescent male and female mice. Front Pharmacol. (2019) 10:587. doi: 10.3389/fphar.2019.00587
77. Aspesi D, Farinetti A, Marraudino M, Kojo Morgan GS, Marzola E, Abbate-Daga G, et al. Maternal separation alters the reward system of activity-based anorexia rats. Psychoneuroendocrinology. (2021) 133:105393. doi: 10.1016/j.psyneuen.2021.105393
Keywords: anorexia nervosa, animal model, activity based anorexia, hypothalamus, dopaminergic pathway, gut microbiome, GWAS
Citation: Zhang J and Dulawa SC (2021) The Utility of Animal Models for Studying the Metabo-Psychiatric Origins of Anorexia Nervosa. Front. Psychiatry 12:711181. doi: 10.3389/fpsyt.2021.711181
Received: 18 May 2021; Accepted: 17 September 2021;
Published: 14 October 2021.
Edited by:
Brian H. Harvey, North-West University, South AfricaReviewed by:
Andreas Stengel, Charité – Universitätsmedizin Berlin, GermanyStefanie Trinh, University Hospital RWTH Aachen, Germany
Copyright © 2021 Zhang and Dulawa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Stephanie C. Dulawa, sdulawa@ucsd.edu